Cargando…
Male Breast Cancer: From Molecular Genetics to Clinical Management
SIMPLE SUMMARY: Male breast cancer (MBC) is a rare disease. Genetic factors predispose to male breast cancer. Germline and/or genetic and/or epigenetic alterations at the somatic level identify a subset of male breast cancer that could differ from female breast cancer (FBC). Cancer genetic counselin...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030724/ https://www.ncbi.nlm.nih.gov/pubmed/35454911 http://dx.doi.org/10.3390/cancers14082006 |
_version_ | 1784692211868237824 |
---|---|
author | Pensabene, Matilde Von Arx, Claudia De Laurentiis, Michelino |
author_facet | Pensabene, Matilde Von Arx, Claudia De Laurentiis, Michelino |
author_sort | Pensabene, Matilde |
collection | PubMed |
description | SIMPLE SUMMARY: Male breast cancer (MBC) is a rare disease. Genetic factors predispose to male breast cancer. Germline and/or genetic and/or epigenetic alterations at the somatic level identify a subset of male breast cancer that could differ from female breast cancer (FBC). Cancer genetic counseling should be included in the work-up of male breast cancer to identify the possible genetic origin of the tumor and to offer patients and their at-risk family members adequate management. ABSTRACT: MBC is a rare disease accounting for almost 1% of all cancers in men and less than 1% of breast cancer. Emerging data on the genetic drivers of predisposition for MBC are available and different risk factors have been associated with its pathogenesis. Genetic alterations, such as pathogenetic variants in BRCA1/2 and other moderate-/low-penetrance genes, along with non-genetic risk factors, have been recognized as pathogenic factors for MBC. Preventive and therapeutic implications could be related to the detection of alterations in predisposing genes, especially BRCA1/2, and to the identification of oncogenic drivers different from FBC. However, approved treatments for MBC remain the same as FBC. Cancer genetic counseling has to be considered in the diagnostic work-up of MBC with or without positive oncological family history. Here, we review the literature, reporting recent data about this malignancy with a specific focus on epidemiology, and genetic and non-genetic risk factors. We introduce the perspective of cancer genetic counseling for MBC patients and their healthy at-risk family members, with a focus on different hereditary cancer syndromes. |
format | Online Article Text |
id | pubmed-9030724 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90307242022-04-23 Male Breast Cancer: From Molecular Genetics to Clinical Management Pensabene, Matilde Von Arx, Claudia De Laurentiis, Michelino Cancers (Basel) Review SIMPLE SUMMARY: Male breast cancer (MBC) is a rare disease. Genetic factors predispose to male breast cancer. Germline and/or genetic and/or epigenetic alterations at the somatic level identify a subset of male breast cancer that could differ from female breast cancer (FBC). Cancer genetic counseling should be included in the work-up of male breast cancer to identify the possible genetic origin of the tumor and to offer patients and their at-risk family members adequate management. ABSTRACT: MBC is a rare disease accounting for almost 1% of all cancers in men and less than 1% of breast cancer. Emerging data on the genetic drivers of predisposition for MBC are available and different risk factors have been associated with its pathogenesis. Genetic alterations, such as pathogenetic variants in BRCA1/2 and other moderate-/low-penetrance genes, along with non-genetic risk factors, have been recognized as pathogenic factors for MBC. Preventive and therapeutic implications could be related to the detection of alterations in predisposing genes, especially BRCA1/2, and to the identification of oncogenic drivers different from FBC. However, approved treatments for MBC remain the same as FBC. Cancer genetic counseling has to be considered in the diagnostic work-up of MBC with or without positive oncological family history. Here, we review the literature, reporting recent data about this malignancy with a specific focus on epidemiology, and genetic and non-genetic risk factors. We introduce the perspective of cancer genetic counseling for MBC patients and their healthy at-risk family members, with a focus on different hereditary cancer syndromes. MDPI 2022-04-15 /pmc/articles/PMC9030724/ /pubmed/35454911 http://dx.doi.org/10.3390/cancers14082006 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Pensabene, Matilde Von Arx, Claudia De Laurentiis, Michelino Male Breast Cancer: From Molecular Genetics to Clinical Management |
title | Male Breast Cancer: From Molecular Genetics to Clinical Management |
title_full | Male Breast Cancer: From Molecular Genetics to Clinical Management |
title_fullStr | Male Breast Cancer: From Molecular Genetics to Clinical Management |
title_full_unstemmed | Male Breast Cancer: From Molecular Genetics to Clinical Management |
title_short | Male Breast Cancer: From Molecular Genetics to Clinical Management |
title_sort | male breast cancer: from molecular genetics to clinical management |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030724/ https://www.ncbi.nlm.nih.gov/pubmed/35454911 http://dx.doi.org/10.3390/cancers14082006 |
work_keys_str_mv | AT pensabenematilde malebreastcancerfrommoleculargeneticstoclinicalmanagement AT vonarxclaudia malebreastcancerfrommoleculargeneticstoclinicalmanagement AT delaurentiismichelino malebreastcancerfrommoleculargeneticstoclinicalmanagement |